文献速递儿科影像泌尿生殖技术与安全MR

儿科人群对比增强MRI检查后急性肾损伤的风险

Risk of acute kidney injury after contrast-enhanced MRI examinations in a pediatric population.
PubMed 文献 · Eur Radiol · 2024-12-23

该回顾性研究纳入2508例次儿科MRI检查(1996例次增强,512例次未增强),比较钆基对比剂给药与急性肾损伤(AKI)发生的关联。多因素分析显示两组AKI发生率无显著差异(校正OR 1.29,95%CI 0.53-3.11,p=0.58),倾向性评分匹配和逆概率加权分析亦无显著关联(p分别为0.22和0.21)。结论认为儿科患者接受钆基对比剂与AKI发生无显著关联。

要点

  • 儿科增强MRI组AKI发生率为1.5%,未增强组为1.2%。
  • 多因素分析显示钆基对比剂与AKI无显著关联(校正OR 1.29,95%CI 0.53-3.11,p=0.58)。
  • 亚组分析未发现钆基对比剂与任何亚组变量存在显著交互作用。

核心结论

  • 儿科患者接受钆基对比剂给药与急性肾损伤发生无显著关联。

研究设计与样本

  • 回顾性研究,纳入2015年1月1日至2021年6月30日期间接受增强或未增强MRI且有检查前3个月内及检查后2天内身高和血清肌酐数据的儿科患者,共2508例次检查(增强1996例次,未增强512例次),AKI按AKI Network标准定义,采用多变量广义估计方程、倾向性评分分析和逆概率治疗加权分析评估关联。

诊断标准与关键数值

  • AKI依据AKI Network标准定义;增强组AKI发生率1.5%,未增强组1.2%;多变量分析校正OR 1.29(95%CI 0.53-3.11,p=0.58);倾向性评分匹配分析p=0.22,逆概率治疗加权分析p=0.21。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the associations between gadolinium-based contrast agent (GBCA) administration and the occurrence of acute kidney injury (AKI) in pediatric patients, and to determine the risks associated with AKI.

MATERIALS AND METHODS: This retrospective study was conducted on pediatric patients who underwent contrast-enhanced or unenhanced MRI between January 1st, 2015, and June 30th, 2021. Examinations were included if they had data on height and serum creatinine levels within 3 months before and 2 days after the examinations. AKI was defined according to the AKI Network criteria. Multivariable generalized estimating equations, propensity score analyses, and inverse probability of treatment weighting analysis were used to evaluate associations between GBCA and AKI. Subgroup analyses were conducted to evaluate the interaction effects of GBCA and each subgroup variable (age, sex, examination type, admission type, chronic kidney disease stage, diabetes mellitus, cardiovascular disease, or surgery or contrast-enhanced CT performed 7 days before and 2 days after MRI).

RESULTS: A total of 2508 examinations were included (1996 with contrast-enhanced, 512 with unenhanced MRI). AKI occurred in 1.5% of the contrast group and 1.2% of the noncontrast group. Multivariable analysis showed no significant difference in AKI incidence between the groups (adjusted OR, 1.29 [95% CI: 0.53, 3.11]; p = 0.58). Propensity score matching and inverse probability of treatment weighting analysis also showed no significant association (p = 0.22 and p = 0.21, respectively). Subgroup analysis showed no significant interaction between GBCA and any of the subgroup variables.

CONCLUSION: The study found no significant association between gadolinium-based contrast agent administration and the occurrence of acute kidney injury in pediatric patients.

KEY POINTS: Question There is limited data on the development of acute kidney injury following exposure to gadolinium-based contrast agent in pediatric patients. Findings There was no significant association between the administration of gadolinium-based contrast agent and occurrence of acute kidney injury in pediatric patients. Clinical relevance The administration of gadolinium-based contrast agents does not increase the risk of acute kidney injury in pediatric patients following MRI.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jeong H, Kim PH, Jung AY, et al. Risk of acute kidney injury after contrast-enhanced MRI examinations in a pediatric population. Eur Radiol. 2024. PMID: 39714605. doi:10.1007/s00330-024-11315-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。